Relatively few drug/vaccine developers are responsible for the top sellers on this list. [© Robert Hoetink - Fotolia.com]
#8. Menactra
Meningococcal polysaccharide (serogroups A, C, Y, and W-135) diphtheria toxoid conjugate vaccine
2012 sales: €564 million ($735 million)1,2
2011 sales: €427 million ($557 million)1,2,7
% year-to-year sales growth: 32.1%
Developer/Sponsor: Sanofi and Sanofi Pasteur MSD
Indications: Active immunization of individuals nine months through 55 years of age for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135
#7. Varivax
Varicella virus vaccine live
2012 sales: $846 million4
2011 sales: $831 million4
% year-to-year sales growth: 1.8%
Developer/Sponsor: Merck & Co. and Sanofi Pasteur MSD
Indications: Active immunization of persons 12 months of age and older; optional second dose for children 12 months to 12 years of age
#6. Hepatitis franchise
Includes: Hepatitis A vaccine, inactivated (Havrix); Hepatitis A inactivated and hepatitis B (recombinant) vaccine (Twinrix); Hepatitis B vaccine (recombinant)(Engerix-B)
2012 sales: £646 million ($986 million)1,8
2011 sales: $688 million ($1.050 billion)1,8
% year-to-year sales growth: -6.1%
Developer/Sponsor: GlaxoSmithKline
Indications: Active immunization against disease caused by hepatitis A virus for persons ≥12 months of age (Havrix); active immunization of persons 18 years of age or older against disease caused by hepatitis A virus and infection by all known subtypes of hepatitis B virus (Twinrix); and immunization against infection caused by all known subtypes of hepatitis B virus (Engerix-B)
#5. Fluzone®, Fluzone High-Dose and Fluzone Intradermal /Vaxigrip®/ Mutagrip®
Influenza virus vaccine
2012 sales: €884 million ($1.152 billion)1,2
2011 sales: €826 million ($1.077 million)1,2
% year-to-year sales growth: 7.0%
Developer/Sponsor: Sanofi and Sanofi Pasteur MSD
Indications: Active immunization of persons six months of age and older against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. Fluzone High-Dose is indicated for active immunization of persons 65 years of age and older against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine; Fluzone Intradermal indicated for active immunization for use in adults 18 through 64 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine
#4. Infanrix/Pediarix
Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined
2012 sales: £775 million ($1.183 billion)1
2011 sales: £690 million ($1.053 billion)1
% year-to-year sales growth: 12.3%
Developer/Sponsor: GlaxoSmithKline
Indications: Active immunization against diphtheria, tetanus, pertussis, infection caused by all known subtypes of hepatitis B virus, and poliomyelitis. Approved for use as a three-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers; may be given as early as six weeks of age through six years of age (prior to the seventh birthday)
#3. PENTAct-HIB
Hemophilus influenzae type b polysaccharide conjugated to tetanus protein, diphtheria, tetanus, pertussis, and inactivated poliovirus vaccines (types 1, 2, and 3)
2012 sales: $1.522 billion9,10
2011 sales: $1.496 billion9,10
% year-to-year sales growth: 1.7%
Developer/Sponsor: Sanofi and Sanofi Pasteur MSD
Indications: Prevention of invasive infections, e.g., meningitis, septicemia, epiglottitis caused by H influenzae type B, diphtheria, pertussis, tetanus, and poliomyelitis
#2. Gardasil®
Human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant
2012 sales: $1.900 billion11
2011 sales: $1.445 billion12
% year-to-year sales growth: 31.5%
Developer/Sponsor: Merck & Co. and Sanofi Pasteur MSD
Indications: Prevention of vulvar and vaginal cancer; prevention of the following diseases caused by human papillomavirus (HPV) types 6, 11, 16, and 18: cervical cancer; genital warts (condyloma acuminata) and the following precancerous or dysplastic lesions: cervical adenocarcinoma in situ (AIS); cervical intraepithelial neoplasia (CIN) grade 2 and grade 3; vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3; vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3; and CIN grade 1. Also, prevention of genital warts caused by HPV types 6 and 11 in boys and men nine through 26 years of age; and prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 in people ages nine through 26 years.
#1. Prevnar 13®/Prevenar 13
Pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein)
2012 sales: $3.718 billion
2011 sales: $3.657 billion
% year-to-year sales growth: 1.7%
Developer/Sponsor: Pfizer
Indications: Prevention of: pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in persons 50 years of age or older; invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in children six weeks through 17 years of age; otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for use in children six weeks through five years of age
Notes:
1 Figures converted to U.S. dollars via www.xe.com on June 27
2 Figures exclude sales generated for the vaccine by Sanofi Pasteur MSD, which were not disclosed by the joint venture
3 2012 sales figure for Sanofi was obtained by adding Adacel sales results for all four quarters of 2012, as furnished in company press releases. Sanofi did not disclose a full-year 2012 sales figure for the vaccine, as it did in 2011
4 Figures exclude sales generated for the vaccine by Sanofi Pasteur MSD, which were not disclosed by the joint venture, but do include supply sales by Merck to Sanofi Pasteur MSD.
5 2012 sales figure combines Merck’s reported $601 million with $47 million reported by Sanofi Pasteur MSD
6 2011 sales figure combines Merck’s reported $651 million with $44 million reported by Sanofi Pasteur MSD
7 2011 sales figure is an estimate obtained by dividing 2012 figure by percentage increase over 2011, both of which were disclosed by Sanofi earlier this year. See page 7 of Sanofi’s press release announcing results for the fourth quarter and full year of 2012, issued February 7: http://en.sanofi.com/Images/31846_20130207_2012RESULTS_en.pdf
8 GlaxoSmithKline does not disclose sales of its hepatitis vaccines individually. Collectively, the hepatitis franchise account for the second largest components of GSK’s vaccine business, after Infanrix/Pediarix
9 Sanofi does not disclose individual sales of PENTAct-HIB, but combines them with other vaccines in its “Polio/Pertussis/Hib vaccines” category, which finished 2012 with €1.184 billion ($1.543 billion) in combined sales in 2012, 10.1% above 2011’s €1.075 billion ($1.401 billion). The only recent sales figures for the vaccine come from Evaluate Pharma, which reports the vaccine generated $1.522 billion in 2012, up 1.7% from $1.496 billion in 2011. The 2011 figure was also cited by Deutsche Bank in “European Pharmaceuticals,” a report published August 29, 2012. Figures converted to U.S. dollars via www.xe.com on June 27
10 Sanofi sales figures exclude sales generated by Sanofi Pasteur MSD, a 50–50 joint venture of Sanofi and Merck & Co. (known overseas as MSD) which distributes vaccines of both partners in more than a dozen Western European nations, according to its website (www.spmsd.com), including: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, The Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, and U.K.
11 Figure combines $1.631 billion recorded by Merck + €206 million ($269 million) recorded by Sanofi Pasteur MSD; Sanofi Pasteur MSD figures converted to U.S. dollars via www.xe.com on June 27
12 Figure combines $1.209 billion recorded by Merck + €181 million ($236 million) recorded by Sanofi Pasteur MSD; Sanofi Pasteur MSD figures converted to U.S. dollars via www.xe.com on June 27